Nav1.7

1

Cheng LJ et al. Effects of Fluvastatin on Characteristics of Stellate Ganglion Neurons in a Rabbit Model of Myocardial Ischemia.
Chin. Med. J., 2016 May , 129 (549-56).

2

Gupta B et al. Antinociceptive properties of shikonin: in vitro and in vivo studies.
Can. J. Physiol. Pharmacol., 2016 Mar 6 , (1-9).

3

Tao H et al. Molecular determinant for the tarantula toxin Jingzhaotoxin-I slowing the fast inactivation of voltage-gated sodium channels.
Toxicon, 2016 Mar 1 , 111 (13-21).

4

Rogers M et al. Characterization of Endogenous Sodium Channels in the ND7-23 Neuroblastoma Cell Line: Implications for Use as a Heterologous Ion Channel Expression System Suitable for Automated Patch Clamp Screening.
Assay Drug Dev Technol, 2016 Mar , 14 (109-30).

5

Chambers C et al. High-Throughput Screening of NaV1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument.
Assay Drug Dev Technol, 2016 Mar , 14 (93-108).

6

Henriques ST et al. Interaction of Tarantula Venom Peptide ProTx-II with Lipid Membranes is a Prerequisite for its Inhibition of Human Voltage-gated Sodium Channel NaV1.7.
J. Biol. Chem., 2016 Jun 16 , ().

7

Xu J et al. Peimine, a main active ingredient of Fritillaria, exhibits anti-inflammatory and pain suppression properties at the cellular level.
Fitoterapia, 2016 Jun , 111 (1-6).

8

Cui HL et al. Catalytic asymmetric hetero-Diels-Alder reactions of enones with isatins to access functionalized spirooxindole tetrahydropyrans: scope, derivatization, and discovery of bioactives.
Org. Biomol. Chem., 2016 Jan 27 , 14 (1777-83).

9

Stueber T et al. Quaternary Lidocaine Derivative QX-314 Activates and Permeates Human TRPV1 and TRPA1 to Produce Inhibition of Sodium Channels and Cytotoxicity.
Anesthesiology, 2016 Feb 9 , ().

10

Murray JK et al. Single Residue Substitutions That Confer NaV Subtype Selectivity in the NaV1.7 Inhibitory Peptide GpTx-1.
J. Med. Chem., 2016 Feb 18 , ().

11

Shcherbatko A et al. Engineering Highly Potent and Selective Microproteins Against Nav1.7 Sodium Channel for Treatment of Pain.
J. Biol. Chem., 2016 Apr 22 , ().

12

Frost JM et al. Substituted Indazoles as Nav1.7 Blockers for the Treatment of Pain.
J. Med. Chem., 2016 Apr 14 , 59 (3373-91).

13

Zhang H et al. Optical electrophysiology for probing function and pharmacology of voltage-gated ion channels.
Elife, 2016 , 5 ().

14

Lazcano-Pérez F et al. Activity of Palythoa caribaeorum Venom on Voltage-Gated Ion Channels in Mammalian Superior Cervical Ganglion Neurons.
Toxins (Basel), 2016 , 8 ().

15

Zhao Y et al. Regulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells.
BMC Cardiovasc Disord, 2016 , 16 (1).

16

Ji RR Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms?
Pulm Pharmacol Ther, 2015 Sep 6 , ().

17

Salas MM et al. Tetrodotoxin suppresses thermal hyperalgesia and mechanical allodynia in a rat full thickness thermal injury pain model.
Neurosci. Lett., 2015 Sep 28 , 607 (108-113).

18

Remacle AG et al. Matrix Metalloproteinase (MMP) Proteolysis of the Extracellular Loop of Voltage-gated Sodium Channels and Potential Alterations in Pain Signaling.
J. Biol. Chem., 2015 Sep 18 , 290 (22939-44).

19

Namer B et al. Specific changes in conduction velocity recovery cycles of single nociceptors in a patient with erythromelalgia with the I848T gain-of-function mutation of Nav1.7.
Pain, 2015 Sep , 156 (1637-46).

20

Estacion M et al. Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation.
J. Neurophysiol., 2015 Sep , 114 (1554-64).

21

Klint JK et al. Rational engineering defines a molecular switch that is essential for activity of spider-venom peptides against the analgesics target NaV1.7.
Mol. Pharmacol., 2015 Oct 1 , ().

22

Kim DT et al. Bilateral congenital corneal anesthesia in a patient with SCN9A mutation, confirmed primary erythromelalgia, and paroxysmal extreme pain disorder.
J AAPOS, 2015 Oct , 19 (478-9).

23

Murray JK et al. Sustained inhibition of the NaV1.7 sodium channel by engineered dimers of the domain II binding peptide GpTx-1.
Bioorg. Med. Chem. Lett., 2015 Nov 1 , 25 (4866-71).

24

Zheng G et al. Chronic stress and peripheral pain: Evidence for distinct, region-specific changes in visceral and somatosensory pain regulatory pathways.
Exp. Neurol., 2015 Nov , 273 (301-11).

25

Emery EC et al. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations.
J. Neurosci., 2015 May 20 , 35 (7674-81).

26

Stadler T et al. Erythromelalgia mutation Q875E Stabilizes the activated state of sodium channel Nav1.7.
J. Biol. Chem., 2015 Mar 6 , 290 (6316-25).

27

Murray JK et al. Engineering Potent and Selective Analogues of GpTx-1, a Tarantula Venom Peptide Antagonist of the NaV1.7 Sodium Channel.
J. Med. Chem., 2015 Mar 12 , 58 (2299-314).

28

Tigerholm J et al. C-fiber recovery cycle supernormality depends on ion concentration and ion channel permeability.
Biophys. J., 2015 Mar 10 , 108 (1057-71).

29

Rahman W et al. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat.
Neuroscience, 2015 Jun 4 , 295 (103-16).

30

Hoeijmakers JG et al. Painful peripheral neuropathy and sodium channel mutations.
Neurosci. Lett., 2015 Jun 2 , 596 (51-9).

31

Du Y et al. Development and validation of a thallium flux-based functional assay for the sodium channel NaV1.7 and its utility for lead discovery and compound profiling.
ACS Chem Neurosci, 2015 Jun 17 , 6 (871-8).

32

Bogdanova-Mihaylova P et al. SCN9A-associated congenital insensitivity to pain and anosmia in an Irish patient.
J. Peripher. Nerv. Syst., 2015 Jun , 20 (86-7).

33

Han C et al. The Domain II S4-S5 Linker in Nav1.9: A Missense Mutation Enhances Activation, Impairs Fast Inactivation, and Produces Human Painful Neuropathy.
Neuromolecular Med., 2015 Jun , 17 (158-69).

34

Cai T et al. Mapping the interaction site for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels.
Peptides, 2015 Jun , 68 (148-56).

35

Torregrosa R et al. Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.
Bioorg. Med. Chem., 2015 Jul 1 , 23 (3655-66).

36

Wang ZJ et al. Inhibition of Nav1.7 channels by methyl eugenol as a mechanism underlying its antinociceptive and anesthetic actions.
Acta Pharmacol. Sin., 2015 Jul , 36 (791-9).

37

Chow CY et al. Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula.
Toxins (Basel), 2015 Jul , 7 (2494-513).

38

Fukuoka T et al. De novo expression of Nav1.7 in injured putative proprioceptive afferents: Multiple tetrodotoxin-sensitive sodium channels are retained in the rat dorsal root after spinal nerve ligation.
Neuroscience, 2015 Jan 22 , 284 (693-706).

39

Lynch SM et al. Dibenzazepines and dibenzoxazepines as sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (43-7).

40

Lynch SM et al. N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (48-52).

41

Stoetzer C et al. Methadone is a local anaesthetic-like inhibitor of neuronal Na+ channels and blocks excitability of mouse peripheral nerves.
Br J Anaesth, 2015 Jan , 114 (110-20).

42

Lim BC et al. Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?
Epilepsy Res., 2015 Jan , 109 (34-9).

43

Zhang F et al. Natural mutations change the affinity of μ-theraphotoxin-Hhn2a to voltage-gated sodium channels.
Toxicon, 2015 Jan , 93 (24-30).

44

Feng B et al. Experimental and computational evidence for an essential role of NaV1.6 in spike initiation at stretch-sensitive colorectal afferent endings.
J. Neurophysiol., 2015 Feb 4 , (jn.00717.2014).

45

Vandael DH et al. Reduced availability of voltage-gated sodium channels by depolarization or blockade by tetrodotoxin boosts burst firing and catecholamine release in mouse chromaffin cells.
J. Physiol. (Lond.), 2015 Feb 15 , 593 (905-27).

46

Bi RY et al. A new hypothesis of sex-differences in temporomandibular disorders: estrogen enhances hyperalgesia of inflamed TMJ through modulating voltage-gated sodium channel 1.7 in trigeminal ganglion?
Med. Hypotheses, 2015 Feb , 84 (100-3).

47

Suter MR et al. p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder.
Anesthesiology, 2015 Feb , 122 (414-23).

48

Obergrussberger A et al. Automated Patch Clamp Meets High-Throughput Screening: 384 Cells Recorded in Parallel on a Planar Patch Clamp Module.
J Lab Autom, 2015 Dec 23 , ().

49

Ahuja S et al. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist.
Science, 2015 Dec 18 , 350 (aac5464).

50

Spencer NJ Switching off pain at the source: is this the end for opioid pain relief?
Pain Manag, 2015 Dec 17 , ().

51

Szabat M et al. High-content screening identifies a role for Na(+) channels in insulin production.
R Soc Open Sci, 2015 Dec , 2 (150306).

52

Cardoso FC et al. Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens.
Mol. Pharmacol., 2015 Aug , 88 (291-303).

53

Pucca MB et al. Electrophysiological characterization of the first Tityus serrulatus alpha-like toxin, Ts5: Evidence of a pro-inflammatory toxin on macrophages.
Biochimie, 2015 Aug , 115 (8-16).

54

Wang Y et al. Comparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and Lidocaine.
PLoS ONE, 2015 , 10 (e0128653).

55

Matson DJ et al. Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of Pain.
PLoS ONE, 2015 , 10 (e0138140).

56

Doran C et al. Mouse DRG Cell Line with Properties of Nociceptors.
PLoS ONE, 2015 , 10 (e0128670).

57

Koenig J et al. Regulation of Nav1.7: A Conserved SCN9A Natural Antisense Transcript Expressed in Dorsal Root Ganglia.
PLoS ONE, 2015 , 10 (e0128830).

58

Rice FL et al. Sodium channel Nav1.7 in vascular myocytes, endothelium, and innervating axons in human skin.
Mol Pain, 2015 , 11 (26).

59

Kharatmal SB et al. Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy.
Mini Rev Med Chem, 2015 , 15 (1134-47).

60

Bao L Trafficking regulates the subcellular distribution of voltage-gated sodium channels in primary sensory neurons.
Mol Pain, 2015 , 11 (61).

61

Imai N et al. Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder.
J Headache Pain, 2015 , 16 (519).

62

Habib AM et al. Sodium channels and pain.
Handb Exp Pharmacol, 2015 , 227 (39-56).

63

King GF et al. No gain, no pain: NaV1.7 as an analgesic target.
ACS Chem Neurosci, 2014 Sep 17 , 5 (749-51).

64

Sun S et al. The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.
Bioorg. Med. Chem. Lett., 2014 Sep 15 , 24 (4397-401).

65

Huang J et al. Depolarized inactivation overcomes impaired activation to produce DRG neuron hyperexcitability in a Nav1.7 mutation in a patient with distal limb pain.
J. Neurosci., 2014 Sep 10 , 34 (12328-40).

66

Ho GD et al. Discovery of pyrrolo-benzo-1,4-diazines as potent Na(v)1.7 sodium channel blockers.
Bioorg. Med. Chem. Lett., 2014 Sep 1 , 24 (4110-3).

67

Ding T et al. Neural tissue engineering scaffold with sustained RAPA release relieves neuropathic pain in rats.
Life Sci., 2014 Sep 1 , 112 (22-32).

68

Snyder LM et al. An SCN9A variant, known to cause pain, is now found to cause itch.
Pain, 2014 Sep , 155 (1677-8).

69

Devigili G et al. Paroxysmal itch caused by gain-of-function Nav1.7 mutation.
Pain, 2014 Sep , 155 (1702-7).

70

Greaves E et al. Elevated peritoneal expression and estrogen regulation of nociceptive ion channels in endometriosis.
J. Clin. Endocrinol. Metab., 2014 Sep , 99 (E1738-43).

71

Horishita T et al. Neurosteroids allopregnanolone sulfate and pregnanolone sulfate have diverse effect on the α subunit of the neuronal voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 expressed in xenopus oocytes.
Anesthesiology, 2014 Sep , 121 (620-31).

72

Meglič A et al. Painful micturition in a small child: an unusual clinical picture of paroxysmal extreme pain disorder.
Pediatr. Nephrol., 2014 Sep , 29 (1643-6).

73

Huang Y et al. The role of TNF-alpha/NF-kappa B pathway on the up-regulation of voltage-gated sodium channel Nav1.7 in DRG neurons of rats with diabetic neuropathy.
Neurochem. Int., 2014 Sep , 75 (112-9).

74

Sun S et al. Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010.
Pharm Pat Anal, 2014 Sep , 3 (509-21).

75

Ramirez JD et al. Null mutation in SCN9A in which noxious stimuli can be detected in the absence of pain.
Neurology, 2014 Oct 21 , 83 (1577-80).

76

Harrer JU et al. Neuropathic pain in two-generation twins carrying the sodium channel Nav1.7 functional variant R1150W.
Pain, 2014 Oct , 155 (2199-203).

77

Cregg R et al. Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.
Br. J. Pharmacol., 2014 Oct , 171 (4455-63).

78

Hoeijmakers JG et al. Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?
Trends Mol Med, 2014 Oct , 20 (544-50).

79

Green BR et al. Structure and function of μ-conotoxins, peptide-based sodium channel blockers with analgesic activity.
Future Med Chem, 2014 Oct , 6 (1677-98).

80

Tan ZY et al. Protein kinase C enhances human sodium channel hNav1.7 resurgent currents via a serine residue in the domain III-IV linker.
FEBS Lett., 2014 Nov 3 , 588 (3964-9).

81

Zhang Q et al. Na+ current properties in islet α- and β-cells reflect cell-specific Scn3a and Scn9a expression.
J. Physiol. (Lond.), 2014 Nov 1 , 592 (4677-96).

82

Bartholomew F et al. Channelopathy: a novel mutation in the SCN9A gene causes insensitivity to pain and autonomic dysregulation.
Br. J. Dermatol., 2014 Nov , 171 (1268-70).

83

Mansouri M et al. A novel nonsense mutation in SCN9A in a Moroccan child with congenital insensitivity to pain.
Pediatr. Neurol., 2014 Nov , 51 (741-4).

84

Xu L et al. Functional characterization of two novel scorpion sodium channel toxins from Lychas mucronatus.
Toxicon, 2014 Nov , 90 (318-25).

85

Waxman SG et al. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use.
Lancet Neurol, 2014 Nov , 13 (1152-60).

86

Klint JK et al. Isolation, synthesis and characterization of ω-TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type Cav channels.
Biochem. Pharmacol., 2014 May 15 , 89 (276-86).

87

Han C et al. The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability.
J. Neurol. Neurosurg. Psychiatr., 2014 May , 85 (499-505).

88

Zidar N et al. Substituted 4-phenyl-2-aminoimidazoles and 4-phenyl-4,5-dihydro-2-aminoimidazoles as voltage-gated sodium channel modulators.
Eur J Med Chem, 2014 Mar 3 , 74 (23-30).

89

Thériault O et al. Modulation of peripheral Na(+) channels and neuronal firing by n-butyl-p-aminobenzoate.
Eur. J. Pharmacol., 2014 Mar 15 , 727 (158-66).

90

Black JA et al. Nav1.9 expression in magnocellular neurosecretory cells of supraoptic nucleus.
Exp. Neurol., 2014 Mar , 253 (174-9).

91

Okura D et al. The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes.
Anesth. Analg., 2014 Mar , 118 (554-62).

92

Lee JH et al. A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief.
Cell, 2014 Jun 5 , 157 (1393-404).

93

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

94

Zhang H et al. Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy.
Anesthesiology, 2014 Jun , 120 (1463-75).

95

Bennett DL et al. Painful and painless channelopathies.
Lancet Neurol, 2014 Jun , 13 (587-99).

96

Brouwer BA et al. Painful neuropathies: the emerging role of sodium channelopathies.
J. Peripher. Nerv. Syst., 2014 Jun , 19 (53-65).

97

Huang J et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy.
Brain, 2014 Jun , 137 (1627-42).

98

Foadi N et al. Inhibition of voltage-gated Na⁺ channels by the synthetic cannabinoid ajulemic acid.
Anesth. Analg., 2014 Jun , 118 (1238-45).

99

Minett MS et al. Pain without nociceptors? Nav1.7-independent pain mechanisms.
Cell Rep, 2014 Jan 30 , 6 (301-12).

100

Eberhardt M et al. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation.
J. Biol. Chem., 2014 Jan 24 , 289 (1971-80).

101

Meijer IA et al. An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
Muscle Nerve, 2014 Jan , 49 (134-8).

102

Shorer Z et al. A novel mutation in SCN9A in a child with congenital insensitivity to pain.
Pediatr. Neurol., 2014 Jan , 50 (73-6).

103

Zhang J et al. Overexpression of myocardin induces partial transdifferentiation of human-induced pluripotent stem cell-derived mesenchymal stem cells into cardiomyocytes.
Physiol Rep, 2014 Feb 1 , 2 (e00237).

104

Tamura R et al. Up-regulation of NaV1.7 sodium channels expression by tumor necrosis factor-α in cultured bovine adrenal chromaffin cells and rat dorsal root ganglion neurons.
Anesth. Analg., 2014 Feb , 118 (318-24).

105

Muroi Y et al. Targeting voltage gated sodium channels NaV1.7, Na V1.8, and Na V1.9 for treatment of pathological cough.
Lung, 2014 Feb , 192 (15-20).

106

Mukai M et al. Evaluation of behavior and expression of NaV1.7 in dorsal root ganglia after sciatic nerve compression and application of nucleus pulposus in rats.
Eur Spine J, 2014 Feb , 23 (463-8).

107

Park JH et al. Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels.
J. Med. Chem., 2014 Aug 14 , 57 (6623-31).

108

Liu Y et al. Synthesis and analgesic effects of μ-TRTX-Hhn1b on models of inflammatory and neuropathic pain.
Toxins (Basel), 2014 Aug , 6 (2363-78).

109

Yip TS et al. SCN1A variations and response to multiple antiepileptic drugs.
Pharmacogenomics J., 2014 Aug , 14 (385-9).

110

Themistocleous AC et al. The clinical approach to small fibre neuropathy and painful channelopathy.
Pract Neurol, 2014 Apr 28 , ().

111

Sadamasu A et al. Upregulation of NaV1.7 in dorsal root ganglia after intervertebral disc injury in rats.
Spine, 2014 Apr 1 , 39 (E421-6).

112

Vasylyev DV et al. Dynamic-clamp analysis of wild-type human Nav1.7 and erythromelalgia mutant channel L858H.
J. Neurophysiol., 2014 Apr , 111 (1429-43).

113

Zimmer T et al. Voltage-gated sodium channels in the mammalian heart.
Glob Cardiol Sci Pract, 2014 , 2014 (449-63).

114

Gingras J et al. Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain.
PLoS ONE, 2014 , 9 (e105895).

115

Li Y et al. Assembly and validation of versatile transcription activator-like effector libraries.
Sci Rep, 2014 , 4 (4857).

116

Lampert A et al. Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents.
Handb Exp Pharmacol, 2014 , 221 (91-110).

117

Cao J et al. Intrathecal injection of fluorocitric acid inhibits the activation of glial cells causing reduced mirror pain in rats.
BMC Anesthesiol, 2014 , 14 (119).

118

Minett MS et al. Significant determinants of mouse pain behaviour.
PLoS ONE, 2014 , 9 (e104458).

119

Petersson ME et al. Differential axonal conduction patterns of mechano-sensitive and mechano-insensitive nociceptors--a combined experimental and modelling study.
PLoS ONE, 2014 , 9 (e103556).

120

Cioli C et al. Differences in human cortical gene expression match the temporal properties of large-scale functional networks.
PLoS ONE, 2014 , 9 (e115913).

121

Laedermann CJ et al. Ubiquitylation of voltage-gated sodium channels.
Handb Exp Pharmacol, 2014 , 221 (231-50).

122

Liu Z et al. Repeated functional convergent effects of NaV1.7 on acid insensitivity in hibernating mammals.
Proc. Biol. Sci., 2014 , 281 (20132950).

123

Abdelsayed M et al. Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes.
Channels (Austin), 2013 May-Jun , 7 (146-52).

124

Ahn HS et al. Differential effect of D623N variant and wild-type Na(v)1.7 sodium channels on resting potential and interspike membrane potential of dorsal root ganglion neurons.
Brain Res., 2013 Sep 5 , 1529 (165-77).

125

Wu Z et al. Full-length membrane-bound tumor necrosis factor-α acts through tumor necrosis factor receptor 2 to modify phenotype of sensory neurons.
Pain, 2013 Sep , 154 (1778-82).

126

Mulley JC et al. Role of the sodium channel SCN9A in genetic epilepsy with febrile seizures plus and Dravet syndrome.
Epilepsia, 2013 Sep , 54 (e122-6).

127

Rowe AH et al. Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin.
Science, 2013 Oct 25 , 342 (441-6).

128

Yang S et al. Discovery of a selective NaV1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models.
Proc. Natl. Acad. Sci. U.S.A., 2013 Oct 22 , 110 (17534-9).

129

Zhang XY et al. Gain-of-function mutations in SCN11A cause familial episodic pain.
Am. J. Hum. Genet., 2013 Nov 7 , 93 (957-66).

130

Yang Y et al. Molecular architecture of a sodium channel S6 helix: radial tuning of the voltage-gated sodium channel 1.7 activation gate.
J. Biol. Chem., 2013 May 10 , 288 (13741-7).

131

Kalezic I et al. In vivo and ex vivo inhibition of spinal nerve ligation-induced ectopic activity by sodium channel blockers correlate to in vitro inhibition of NaV1.7 and clinical efficacy: a pharmacokinetic-pharmacodynamic translational approach.
Pharm. Res., 2013 May , 30 (1409-22).

132

Estacion M et al. A new Nav1.7 mutation in an erythromelalgia patient.
Biochem. Biophys. Res. Commun., 2013 Mar 1 , 432 (99-104).

133

Minassian NA et al. Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin, Huwentoxin-IV (μ-TRTX-Hh2a).
J. Biol. Chem., 2013 Jun 12 , ().

134

Revell JD et al. Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena.
Peptides, 2013 Jun , 44 (40-6).

135

Liang L et al. Protein kinase B/Akt is required for complete Freund's adjuvant-induced upregulation of Nav1.7 and Nav1.8 in primary sensory neurons.
J Pain, 2013 Jun , 14 (638-47).

136

Cregg R et al. Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia.
Neuromolecular Med., 2013 Jun , 15 (265-78).

137

McCormack K et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jul 16 , 110 (E2724-32).

138

Liu Z et al. Structure and function of hainantoxin-III, a selective antagonist of neuronal tetrodotoxin-sensitive voltage-gated sodium channels isolated from the Chinese bird spider Ornithoctonus hainana.
J. Biol. Chem., 2013 Jul 12 , 288 (20392-403).

139

Tsunozaki M et al. A 'toothache tree' alkylamide inhibits Aδ mechanonociceptors to alleviate mechanical pain.
J. Physiol. (Lond.), 2013 Jul 1 , 591 (3325-40).

140

Galloway C et al. Increases in inflammatory mediators in DRG implicate in the pathogenesis of painful neuropathy in Type 2 diabetes.
Cytokine, 2013 Jul , 63 (1-5).

141

Waxman SG Painful Na-channelopathies: an expanding universe.
Trends Mol Med, 2013 Jul , 19 (406-9).

142

Norinder U et al. QSAR investigation of NaV1.7 active compounds using the SVM/Signature approach and the Bioclipse Modeling platform.
Bioorg. Med. Chem. Lett., 2013 Jan 1 , 23 (261-3).

143

Reeder JE et al. Polymorphism in the SCN9A voltage-gated sodium channel gene associated with interstitial cystitis/bladder pain syndrome.
Urology, 2013 Jan , 81 (210.e1-4).

144

Suter MR et al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state.
Anesthesiology, 2013 Jan , 118 (160-72).

145

Persson AK et al. Neuropathy-associated Nav1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons.
Ann. Neurol., 2013 Jan , 73 (140-5).

146

Zhang JL et al. Gabapentin reduces allodynia and hyperalgesia in painful diabetic neuropathy rats by decreasing expression level of Nav1.7 and p-ERK1/2 in DRG neurons.
Brain Res., 2013 Feb 1 , 1493 (13-8).

147

Zhang LM et al. [Association between mutations of SCN9A gene and pain related to Parkinsonism].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2013 Feb , 30 (17-20).

148

Duan G et al. A single-nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in the general population.
Anesthesiology, 2013 Feb , 118 (436-42).

149

Tanzi S et al. Ion channel recordings on an injection-molded polymer chip.
Lab Chip, 2013 Dec 21 , 13 (4784-93).

150

Staunton CA et al. Ion channels and osteoarthritic pain: potential for novel analgesics.
Curr Pain Headache Rep, 2013 Dec , 17 (378).

151

Doppler K et al. [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment].
Nervenarzt, 2013 Dec , 84 (1428-35).

152

Campbell TM et al. Functional expression of the voltage-gated sodium channel, Nav1.7, underlies epidermal growth factor-mediated invasion in human [R1.S1] non-small cell lung cancer cells.
J. Cell. Sci., 2013 Aug 28 , ().

153

Huang J et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons.
J. Neurosci., 2013 Aug 28 , 33 (14087-97).

154

Dustrude ET et al. CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.
J. Biol. Chem., 2013 Aug 23 , 288 (24316-31).

155

Abbas N et al. The scorpion toxin Amm VIII induces pain hypersensitivity through gain-of-function of TTX-sensitive Na⁺ channels.
Pain, 2013 Aug , 154 (1204-15).

156

Xie W et al. Knockdown of sodium channel NaV1.6 blocks mechanical pain and abnormal bursting activity of afferent neurons in inflamed sensory ganglia.
Pain, 2013 Aug , 154 (1170-80).

157

Yuan J et al. Hereditary sensory and autonomic neuropathy type IID caused by an SCN9A mutation.
Neurology, 2013 Apr 30 , 80 (1641-9).

158

Nemoto T et al. Endothelin-1-induced down-regulation of NaV1.7 expression in adrenal chromaffin cells: attenuation of catecholamine secretion and tau dephosphorylation.
FEBS Lett., 2013 Apr 2 , 587 (898-905).

159

Klein CJ et al. Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia.
J. Neurol. Neurosurg. Psychiatr., 2013 Apr , 84 (386-91).

160

Kim MK et al. Autonomic dysfunction in SCN9A-associated primary erythromelalgia.
Clin. Auton. Res., 2013 Apr , 23 (105-7).

161

Wu MT et al. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers.
PLoS ONE, 2013 , 8 (e55212).

162

Black JA et al. NaV1.7: stress-induced changes in immunoreactivity within magnocellular neurosecretory neurons of the supraoptic nucleus.
Mol Pain, 2013 , 9 (39).

163

Zhou X et al. Modulation of mononuclear phagocyte inflammatory response by liposome-encapsulated voltage gated sodium channel inhibitor ameliorates myocardial ischemia/reperfusion injury in rats.
PLoS ONE, 2013 , 8 (e74390).

164

Heimann D et al. Linkage between Increased Nociception and Olfaction via a SCN9A Haplotype.
PLoS ONE, 2013 , 8 (e68654).

165

Rong M et al. Native pyroglutamation of huwentoxin-IV: a post-translational modification that increases the trapping ability to the sodium channel.
PLoS ONE, 2013 , 8 (e65984).

166

Kennedy PG et al. Varicella-Zoster Viruses Associated with Post-Herpetic Neuralgia Induce Sodium Current Density Increases in the ND7-23 Nav-1.8 Neuroblastoma Cell Line.
PLoS ONE, 2013 , 8 (e51570).

167

Durek T et al. Chemical engineering and structural and pharmacological characterization of the α-scorpion toxin OD1.
ACS Chem. Biol., 2013 , 8 (1215-22).

168

Zufall F et al. Link between pain and olfaction in an inherited sodium channelopathy.
Arch. Neurol., 2012 Sep 1 , 69 (1119-23).

169

Han C et al. Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy.
Brain, 2012 Sep , 135 (2613-28).

170

Jakob A et al. Primary erythromelalgia in a 12-year-old boy: positive response to sodium channel blockers despite negative SCN9A mutations.
Klin Padiatr, 2012 Sep , 224 (309-12).

171

Greenbaum L et al. Contribution of genetic variants to pain susceptibility in Parkinson disease.
Eur J Pain, 2012 Oct , 16 (1243-50).

172

Goldberg YP et al. Human Mendelian pain disorders: a key to discovery and validation of novel analgesics.
Clin. Genet., 2012 Oct , 82 (367-73).

173

Hoeijmakers JG et al. Genetic aspects of sodium channelopathy in small fiber neuropathy.
Clin. Genet., 2012 Oct , 82 (351-8).

174

Klement G et al. Identification of Novel NaV1.7 Antagonists Using High Throughput Screening Platforms.
Comb. Chem. High Throughput Screen., 2012 Nov 1 , 15 (713-20).

175

Han C et al. Nav1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability.
Neurology, 2012 May 22 , 78 (1635-43).

176

Hodgdon KE et al. Dorsal root ganglia isolated from Nf1+/- mice exhibit increased levels of mRNA expression of voltage-dependent sodium channels.
Neuroscience, 2012 Mar 29 , 206 (237-44).

177

Raouf R et al. Sodium channels and mammalian sensory mechanotransduction.
, 2012 Mar 26 , 8 (21).

178

Ma A et al. A life without pain: congenital insensitivity to pain due to compound heterozygous SCN9A mutation.
J Paediatr Child Health, 2012 Mar , 48 (285-6).

179

Leffler A et al. Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine.
Anesthesiology, 2012 Jun , 116 (1335-46).

180

Liu P et al. Modulation of neuronal sodium channels by the sea anemone peptide BDS-I.
J. Neurophysiol., 2012 Jun , 107 (3155-67).

181

Park JH et al. Cysteine racemization during the Fmoc solid phase peptide synthesis of the Nav1.7-selective peptide--protoxin II.
J. Pept. Sci., 2012 Jul , 18 (442-8).

182

Nguyen HN et al. Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1055-60).

183

Fu LY et al. Sensitivity of cloned muscle, heart and neuronal voltage-gated sodium channels to block by polyamines: A possible basis for modulation of excitability in vivo.
, 2012 Jan 1 , 6 ().

184

Faber CG et al. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy.
Ann. Neurol., 2012 Jan , 71 (26-39).

185

Goldberg YP et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker.
Pain, 2012 Jan , 153 (80-5).

186

Fukuoka T et al. Re-evaluation of the phenotypic changes in L4 dorsal root ganglion neurons after L5 spinal nerve ligation.
Pain, 2012 Jan , 153 (68-79).

187

Zhang J et al. Regulation of Cell Proliferation of Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells via Ether a go-go 1 (hEAG1) Potassium Channel.
, 2012 Feb 22 , ().

188

Hoeijmakers JG et al. Small nerve fibres, small hands and small feet: a new syndrome of pain, dysautonomia and acromesomelia in a kindred with a novel NaV1.7 mutation.
Brain, 2012 Feb , 135 (345-58).

189

Skeik N et al. Severe case and literature review of primary erythromelalgia: novel SCN9A gene mutation.
Vasc Med, 2012 Feb , 17 (44-9).

190

Morales PS et al. Paediatric hypertension-associated erythromelalgia responds to corticosteroids and is not associated with SCN9A mutations.
Rheumatology (Oxford), 2012 Dec , 51 (2295-6).

191

Ding H et al. Alterations of gene expression of sodium channels in dorsal root ganglion neurons of estrogen receptor knockout (ERKO) mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Endocrine, 2012 Aug , 42 (118-24).

192

Hu F et al. 17β-Estradiol regulates the gene expression of voltage-gated sodium channels: role of estrogen receptor α and estrogen receptor β.
Endocrine, 2012 Apr , 41 (274-80).

193

Vargas-Alarcón G et al. A SCN9A gene-encoded dorsal root ganglia sodium channel polymorphism associated with severe fibromyalgia.
BMC Musculoskelet Disord, 2012 , 13 (23).

194

Farmer C et al. Splice variants of Na(V)1.7 sodium channels have distinct β subunit-dependent biophysical properties.
PLoS ONE, 2012 , 7 (e41750).

195

Klinger AB et al. Sea-anemone toxin ATX-II elicits A-fiber-dependent pain and enhances resurgent and persistent sodium currents in large sensory neurons.
Mol Pain, 2012 , 8 (69).

196

Holliday KL et al. The non-synonymous SNP, R1150W, in SCN9A is not associated with chronic widespread pain susceptibility.
Mol Pain, 2012 , 8 (72).

197

Black JA et al. Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn.
Mol Pain, 2012 , 8 (82).

198

Minett MS et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons.
Nat Commun, 2012 , 3 (791).

199

Yan J et al. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6).
Mol Pain, 2012 , 8 (6).

200

Weinkauf B et al. Local Gene Expression Changes after UV-Irradiation of Human Skin.
PLoS ONE, 2012 , 7 (e39411).

201

Rong M et al. Molecular basis of the tarantula toxin jingzhaotoxin-III (β-TRTX-Cj1α) interacting with voltage sensors in sodium channel subtype Nav1.5.
FASEB J., 2011 Sep , 25 (3177-85).

202

Muroi Y et al. Selective Silencing of NaV1.7 Decreases Excitability and Conduction in Vagal Sensory Neurons.
, 2011 Oct 17 , ().

203

Yuan R et al. Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception.
Pain Med, 2011 Oct , 12 (1510-4).

204

Byers MR et al. Odontoblasts in developing, mature and ageing rat teeth have multiple phenotypes that variably express all nine voltage-gated sodium channels.
Arch. Oral Biol., 2011 Nov , 56 (1199-220).

205

Freilich ER et al. Novel SCN1A mutation in a proband with malignant migrating partial seizures of infancy.
Arch. Neurol., 2011 May , 68 (665-71).

206

Staud R et al. Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain.
Eur J Pain, 2011 Mar , 15 (223-30).

207

Shou WT et al. [Role of voltage-sodium channels in neuropathic pain].
Zhejiang Da Xue Xue Bao Yi Xue Ban, 2011 Mar , 40 (217-21).

208

Valdes AM et al. Role of the Nav1.7 R1150W amino acid change in susceptibility to symptomatic knee osteoarthritis and multiple regional pain.
Arthritis Care Res (Hoboken), 2011 Mar , 63 (440-4).

209

Chowdhury S et al. Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain.
Bioorg. Med. Chem. Lett., 2011 Jun 15 , 21 (3676-81).

210

Park KS et al. Identification and functional characterization of ion channels in CD34(+) hematopoietic stem cells from human peripheral blood.
, 2011 Jun 1 , ().

211

Fukuoka T et al. Comparative study of voltage-gated sodium channel α-subunits in non-overlapping four neuronal populations in the rat dorsal root ganglion.
Neurosci. Res., 2011 Jun , 70 (164-71).

212

Bregman H et al. Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
J. Med. Chem., 2011 Jul 14 , 54 (4427-45).

213

Okumura A et al. Refractory neonatal epilepsy with a de novo duplication of chromosome 2q24.2q24.3.
Epilepsia, 2011 Jul , 52 (e66-9).

214

Liu M et al. The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain.
Pain Med, 2011 Jul , 12 Suppl 3 (S93-9).

215

Ho C et al. Single-cell analysis of sodium channel expression in dorsal root ganglion neurons.
Mol. Cell. Neurosci., 2011 Jan , 46 (159-66).

216

Widmark J et al. Differential evolution of voltage-gated sodium channels in tetrapods and teleost fishes.
Mol. Biol. Evol., 2011 Jan , 28 (859-71).

217

Huang ZJ et al. Topical application of compound Ibuprofen suppresses pain by inhibiting sensory neuron hyperexcitability and neuroinflammation in a rat model of intervertebral foramen inflammation.
J Pain, 2011 Jan , 12 (141-52).

218

Choi JS et al. Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons.
Nat Rev Neurol, 2011 Jan , 7 (51-5).

219

Dabby R et al. Chronic non-paroxysmal neuropathic pain - Novel phenotype of mutation in the sodium channel SCN9A gene.
J. Neurol. Sci., 2011 Feb 15 , 301 (90-2).

220

Theile JW et al. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents.
J. Physiol. (Lond.), 2011 Feb 1 , 589 (597-608).

221

Panigel J et al. A point mutation at F1737 of the human Nav1.7 sodium channel decreases inhibition by local anesthetics.
J. Neurogenet., 2011 Dec , 25 (134-9).

222

Xiao Y et al. Common molecular determinants of tarantula huwentoxin-IV inhibition of Na+ channel voltage sensors in domains II and IV.
J. Biol. Chem., 2011 Aug 5 , 286 (27301-10).

223

Kis-Toth K et al. Voltage-gated sodium channel Nav1.7 maintains the membrane potential and regulates the activation and chemokine-induced migration of a monocyte-derived dendritic cell subset.
J. Immunol., 2011 Aug 1 , 187 (1273-80).

224

Persson AK et al. NaV1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas.
Exp. Neurol., 2011 Aug , 230 (273-9).

225

Weiss J et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia.
Nature, 2011 Apr 14 , 472 (186-90).

226

Gurkiewicz M et al. Kinetic modeling of Nav1.7 provides insight into erythromelalgia-associated F1449V mutation.
J. Neurophysiol., 2011 Apr , 105 (1546-57).

227

Ahn HS et al. Nav1.7 is the predominant sodium channel in rodent olfactory sensory neurons.
Mol Pain, 2011 , 7 (32).

228

Estacion M et al. Intra- and interfamily phenotypic diversity in pain syndromes associated with a gain-of-function variant of NaV1.7.
Mol Pain, 2011 , 7 (92).

229

Zhang L et al. Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy.
Eur J Dermatol, 2010 Nov-Dec , 20 (763-7).

230

Tyagarajan S et al. Substituted biaryl pyrazoles as sodium channel blockers.
Bioorg. Med. Chem. Lett., 2010 Sep 15 , 20 (5480-3).

231

Fukuoka T et al. Laminae-specific distribution of alpha-subunits of voltage-gated sodium channels in the adult rat spinal cord.
Neuroscience, 2010 Sep 1 , 169 (994-1006).

232

Cox JJ et al. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations.
Hum. Mutat., 2010 Sep , 31 (E1670-86).

233

Wang SY et al. Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner.
Anesthesiology, 2010 Sep , 113 (655-65).

234

Lötsch J et al. Pharmacogenetics of new analgesics.
, 2010 Oct 13 , ().

235

Ahn HS et al. A new Nav1.7 sodium channel mutation I234T in a child with severe pain.
Eur J Pain, 2010 Oct , 14 (944-50).

236

Chen R et al. Electrical injury alters ion channel expression levels and electrophysiological properties in rabbit dorsal root ganglia neurons.
, 2010 Nov 10 , ().

237

Park JH et al. High expression of large-conductance Ca(2+)-activated K(+) channel in the CD133(+) subpopulation of SH-SY5Y neuroblastoma cells.
, 2010 May 7 , ().

238

Gao R et al. Expression of voltage-gated sodium channel alpha subunit in human ovarian cancer.
Oncol. Rep., 2010 May , 23 (1293-9).

239

Reimann F et al. Pain perception is altered by a nucleotide polymorphism in SCN9A.
Proc. Natl. Acad. Sci. U.S.A., 2010 Mar 16 , 107 (5148-53).

240

de Rooij AM et al. No mutations in the voltage-gated NaV1.7 sodium channel alpha1 subunit gene SCN9A in familial complex regional pain syndrome.
Eur. J. Neurol., 2010 Jun 1 , 17 (808-14).

241

Meisler MH et al. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects.
J. Physiol. (Lond.), 2010 Jun 1 , 588 (1841-8).

242

Lampert A et al. Sodium channelopathies and pain.
Pflugers Arch., 2010 Jul , 460 (249-63).

243

Clare JJ Targeting voltage-gated sodium channels for pain therapy.
Expert Opin Investig Drugs, 2010 Jan , 19 (45-62).

244

Fischer TZ et al. Familial pain syndromes from mutations of the NaV1.7 sodium channel.
Ann. N. Y. Acad. Sci., 2010 Jan , 1184 (196-207).

245

Jarecki BW et al. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents.
J. Clin. Invest., 2010 Jan , 120 (369-78).

246

Cregg R et al. Pain Channelopathies.
, 2010 Feb 8 , ().

247

Stamboulian S et al. ERK1/2 Mitogen-Activated Protein Kinase Phosphorylates Sodium Channel Nav1.7 and Alters Its Gating Properties.
J. Neurosci., 2010 Feb 3 , 30 (1637-47).

248

Estacion M et al. Can robots patch-clamp as well as humans? Characterization of a novel sodium channel mutation.
, 2010 Feb 1 , ().

249

Chioni AM et al. Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration.
Int. J. Biochem. Cell Biol., 2010 Feb , 42 (346-58).

250

Guerrini R et al. Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene.
Epilepsia, 2010 Dec , 51 (2474-7).

251

Xiao Y et al. The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation.
Mol. Pharmacol., 2010 Dec , 78 (1124-34).

252

Ghelardini C et al. Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models.
Neuroscience, 2010 Aug 25 , 169 (863-73).

253

Nemoto T et al. Nav1.7-Ca2+ influx-induced increased phosphorylations of extracellular signal-regulated kinase (ERK) and p38 attenuate tau phosphorylation via glycogen synthase kinase-3beta: priming of Nav1.7 gating by ERK and p38.
Eur. J. Pharmacol., 2010 Aug 25 , 640 (20-8).

254

Estacion M et al. A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons.
Exp. Neurol., 2010 Aug , 224 (362-8).

255

Krupp JJ et al. Linkage analysis and functional evaluation of inherited clinical pain conditions.
Methods Mol. Biol., 2010 , 617 (309-25).

256

Estacion M et al. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Mol Pain, 2010 , 6 (35).

257

Cheng X et al. Mutations at opposite ends of the DIII/S4-S5 linker of sodium channel Na V 1.7 produce distinct pain disorders.
Mol Pain, 2010 , 6 (24).

258

Kurban M et al. A nonsense mutation in the SCN9A gene in congenital insensitivity to pain.
Dermatology (Basel), 2010 , 221 (179-83).

259

Persson AK et al. Sodium-calcium exchanger and multiple sodium channel isoforms in intra-epidermal nerve terminals.
Mol Pain, 2010 , 6 (84).

260

Priest BT Future potential and status of selective sodium channel blockers for the treatment of pain.
Curr Opin Drug Discov Devel, 2009 Sep , 12 (682-92).

261

Singh NA et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome.
PLoS Genet., 2009 Sep , 5 (e1000649).

262

Barbara G et al. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids.
J. Neurosci., 2009 Oct 21 , 29 (13106-14).

263

Zsiros E et al. Developmental switch of the expression of ion channels in human dendritic cells.
J. Immunol., 2009 Oct 1 , 183 (4483-92).

264

Dib-Hajj SD et al. Voltage-gated sodium channels: therapeutic targets for pain.
Pain Med, 2009 Oct , 10 (1260-9).

265

Schmalhofer WA et al. A KV2.1 gating modifier binding assay suitable for high throughput screening.
Channels (Austin), 2009 Nov , 3 (437-47).

266

Wang GK et al. State-dependent block of Na+ channels by articaine via the local anesthetic receptor.
J. Membr. Biol., 2009 May , 229 (1-9).

267

Nilsen KB et al. Two novel SCN9A mutations causing insensitivity to pain.
Pain, 2009 May , 143 (155-8).

268

Fischer TZ et al. A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia.
Ann. Neurol., 2009 Jun , 65 (733-41).

269

Kanai T et al. Nav1.7 sodium channel-induced Ca2+ influx decreases tau phosphorylation via glycogen synthase kinase-3beta in adrenal chromaffin cells.
Neurochem. Int., 2009 Jul , 54 (497-505).

270

Meguro K et al. Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells.
Am. J. Physiol. Heart Circ. Physiol., 2009 Jan , 296 (H211-9).

271

Martinez-Lavin M et al. Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain.
Med. Hypotheses, 2009 Jan , 72 (64-6).

272

Nakajima T et al. Eicosapentaenoic acid inhibits voltage-gated sodium channels and invasiveness in prostate cancer cells.
Br. J. Pharmacol., 2009 Feb , 156 (420-31).

273

Danziger N et al. [Congenital insensitivity to pain]
Rev. Neurol. (Paris), 2009 Feb , 165 (129-36).

274

Onkal R et al. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer.
Eur. J. Pharmacol., 2009 Dec 25 , 625 (206-19).

275

Lampert A et al. Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials.
Biochem. Biophys. Res. Commun., 2009 Dec 11 , 390 (319-24).

276

Siqueira SR et al. Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia.
Neuroscience, 2009 Dec 1 , 164 (573-7).

277

Estacion M et al. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability.
Ann. Neurol., 2009 Dec , 66 (862-6).

278

Natkunarajah J et al. Treatment with carbamazepine and gabapentin of a patient with primary erythermalgia (erythromelalgia) identified to have a mutation in the SCN9A gene, encoding a voltage-gated sodium channel.
Clin. Exp. Dermatol., 2009 Dec , 34 (e640-2).

279

Black JA et al. Sodium channel activity modulates multiple functions in microglia.
Glia, 2009 Aug 1 , 57 (1072-81).

280

Macefield VG Developments in autonomic research: a review of the latest literature.
Clin. Auton. Res., 2009 Aug , 19 (193-6).

281

Skali Dahbi S et al. [Primary erythermalgia: efficacy of oxcarbazepine]
, 2009 Apr , 136 (337-40).

282

Yeomans DC et al. Herpes virus-based recombinant herpes vectors: gene therapy for pain and molecular tool for pain science.
Gene Ther., 2009 Apr , 16 (502-8).

283

Desaphy JF et al. Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine.
Pain, 2009 Apr , 142 (225-35).

284

Choi JS et al. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.
Exp. Neurol., 2009 Apr , 216 (383-9).

285

Thakor DK et al. Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation in painful neuropathy.
, 2009 , 5 (14).

286

Gao N et al. Voltage-gated sodium channels in taste bud cells.
, 2009 , 10 (20).

287

Fukuoka T et al. Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons.
J. Comp. Neurol., 2008 Sep 10 , 510 (188-206).

288

Jarecki BW et al. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation.
J. Physiol. (Lond.), 2008 Sep 1 , 586 (4137-53).

289

Xiao Y et al. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration.
J. Biol. Chem., 2008 Oct 3 , 283 (27300-13).

290

Estacion M et al. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders.
J. Neurosci., 2008 Oct 22 , 28 (11079-88).

291

Wang CF et al. Use of bulleyaconitine A as an adjuvant for prolonged cutaneous analgesia in the rat.
Anesth. Analg., 2008 Oct , 107 (1397-405).

292

Nyholt DR et al. A high-density association screen of 155 ion transport genes for involvement with common migraine.
Hum. Mol. Genet., 2008 Nov 1 , 17 (3318-31).

293

Schmalhofer WA et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors.
Mol. Pharmacol., 2008 Nov , 74 (1476-84).

294

London C et al. Imidazopyridines: a novel class of hNav1.7 channel blockers.
Bioorg. Med. Chem. Lett., 2008 Mar 1 , 18 (1696-701).

295

Wang GK et al. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Mol. Pharmacol., 2008 Mar , 73 (940-8).

296

Wang GK et al. Block of persistent late Na+ currents by antidepressant sertraline and paroxetine.
J. Membr. Biol., 2008 Mar , 222 (79-90).

297

Diss JK et al. Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A).
Mol. Cell. Neurosci., 2008 Mar , 37 (537-47).

298

Drenth JP et al. Primary erythermalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A.
Arch Dermatol, 2008 Mar , 144 (320-4).

299

Nakajima T et al. Effect of dexamethasone on voltage-gated Na+ channel in cultured human bronchial smooth muscle cells.
Life Sci., 2008 Jun 6 , 82 (1210-5).

300

Chattopadhyay M et al. Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy.
J. Neurosci., 2008 Jun 25 , 28 (6652-8).

301

Ebermann I et al. Double homozygosity for mutations of AGL and SCN9A mimicking neurohepatopathy syndrome.
Neurology, 2008 Jun 10 , 70 (2343-4).

302

Strickland IT et al. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain.
, 2008 Jul , 12 (564-72).

303

Dray A Neuropathic pain: emerging treatments.
, 2008 Jul , 101 (48-58).

304

Young FB When adaptive processes go awry: gain-of-function in SCN9A.
Clin. Genet., 2008 Jan , 73 (34-6).

305

Kort ME et al. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.
J. Med. Chem., 2008 Feb 14 , 51 (407-16).

306

Wada A et al. Voltage-dependent Na(v)1.7 sodium channels: multiple roles in adrenal chromaffin cells and peripheral nervous system.
Acta Physiol (Oxf), 2008 Feb , 192 (221-31).

307

Krafte DS et al. Sodium channels and nociception: recent concepts and therapeutic opportunities.
, 2008 Feb , 8 (50-6).

308

Black JA et al. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas.
Ann. Neurol., 2008 Dec , 64 (644-53).

309

Lampert A et al. A pore-blocking hydrophobic motif at the cytoplasmic aperture of the closed-state Nav1.7 channel is disrupted by the erythromelalgia-associated F1449V mutation.
J. Biol. Chem., 2008 Aug 29 , 283 (24118-27).

310

Maruta T et al. Lysophosphatidic acid-LPA1 receptor-Rho-Rho kinase-induced up-regulation of Nav1.7 sodium channel mRNA and protein in adrenal chromaffin cells: enhancement of 22Na+ influx, 45Ca2+ influx and catecholamine secretion.
J. Neurochem., 2008 Apr , 105 (401-12).

311

Keh SM et al. Increased nerve fiber expression of sensory sodium channels Nav1.7, Nav1.8, And Nav1.9 in rhinitis.
Laryngoscope, 2008 Apr , 118 (573-9).

312

Trivedi S et al. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators.
, 2008 Apr , 6 (167-79).

313

Dib-Hajj SD et al. Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes.
Adv. Genet., 2008 , 63 (85-110).

314

Cheng X et al. Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decade.
, 2008 , 4 (1).

315

Luo S et al. Nav1.7 expression is increased in painful human dental pulp.
, 2008 , 4 (16).

316

Samuels ME et al. Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythermalgia.
, 2008 , 4 (21).

317

Dib-Hajj SD et al. Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable.
, 2008 , 4 (37).

318

Kaneko Y et al. Expression of Nav1.1 in rat retinal AII amacrine cells.
Neurosci. Lett., 2007 Sep 7 , 424 (83-8).

319

Ahmad S et al. A stop codon mutation in SCN9A causes lack of pain sensation.
Hum. Mol. Genet., 2007 Sep 1 , 16 (2114-21).

320

Kawaguchi A et al. Enhancement of sodium current in NG108-15 cells during neural differentiation is mainly due to an increase in NaV1.7 expression.
Neurochem. Res., 2007 Sep , 32 (1469-75).

321

Yiangou Y et al. Voltage-gated ion channel Nav1.7 innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain).
Neurosci. Lett., 2007 Nov 5 , 427 (77-82).

322

Hoyt SB et al. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Bioorg. Med. Chem. Lett., 2007 Nov 15 , 17 (6172-7).

323

Montagna P Recent advances in the pharmacogenomics of pain and headache.
Neurol. Sci., 2007 May , 28 Suppl 2 (S208-12).

324

Brackenbury WJ et al. Nerve growth factor enhances voltage-gated Na+ channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line.
J. Cell. Physiol., 2007 Mar , 210 (602-8).

325

Sheets PL et al. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity.
J. Physiol. (Lond.), 2007 Jun 15 , 581 (1019-31).

326

Du Y et al. Downregulation of neuronal sodium channel subunits Nav1.1 and Nav1.6 in the sinoatrial node from volume-overloaded heart failure rat.
Pflugers Arch., 2007 Jun , 454 (451-9).

327

Takahashi K et al. A case of primary erythermalgia, wintry hypothermia and encephalopathy.
Neuropediatrics, 2007 Jun , 38 (157-9).

328

Huang X et al. [Expression and function of voltage-gated Na+ channel isoforms in rat sinoatrial node]
Nan Fang Yi Ke Da Xue Xue Bao, 2007 Jan , 27 (52-5).

329

Lee MJ et al. Characterization of a familial case with primary erythromelalgia from Taiwan.
J. Neurol., 2007 Feb , 254 (210-4).

330

Williams BS et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7.
Biochemistry, 2007 Dec 18 , 46 (14693-703).

331

Drenth JP et al. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.
J. Clin. Invest., 2007 Dec , 117 (3603-9).

332

Fertleman CR et al. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome).
Neurology, 2007 Aug 7 , 69 (586-95).

333

Waxman SG Nav1.7, its mutations, and the syndromes that they cause.
Neurology, 2007 Aug 7 , 69 (505-7).

334

Goldberg YP et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations.
Clin. Genet., 2007 Apr , 71 (311-9).

335

Zhang LL et al. Mutation hotspots of SCN9A in primary erythermalgia.
Br. J. Dermatol., 2007 Apr , 156 (767-9).

336

Dray A et al. Arthritis and pain. Future targets to control osteoarthritis pain.
Arthritis Res. Ther., 2007 , 9 (212).

337

Uysal-Onganer P et al. Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel.
Mol. Cancer, 2007 , 6 (76).

338

Han C et al. Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7.
, 2007 , 3 (3).

339

Sheets PL et al. Inhibition of Nav1.7 and Nav1.4 sodium channels by trifluoperazine involves the local anesthetic receptor.
J. Neurophysiol., 2006 Oct , 96 (1848-59).

340

Rogers M et al. The role of sodium channels in neuropathic pain.
Semin. Cell Dev. Biol., 2006 Oct , 17 (571-81).

341

Lampert A et al. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating.
J. Biol. Chem., 2006 Nov 24 , 281 (36029-35).

342

Rush AM et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons.
Proc. Natl. Acad. Sci. U.S.A., 2006 May 23 , 103 (8245-50).

343

Han C et al. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7.
Ann. Neurol., 2006 Mar , 59 (553-8).

344

Brackenbury WJ et al. Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line.
J. Physiol. (Lond.), 2006 Jun 1 , 573 (343-56).

345

Maertens C et al. Potent modulation of the voltage-gated sodium channel Nav1.7 by OD1, a toxin from the scorpion Odonthobuthus doriae.
Mol. Pharmacol., 2006 Jul , 70 (405-14).

346

Leipold E et al. Subtype specificity of scorpion beta-toxin Tz1 interaction with voltage-gated sodium channels is determined by the pore loop of domain 3.
Mol. Pharmacol., 2006 Jul , 70 (340-7).

347

Drenth JP et al. [From gene to disease; primary erythermalgia--a neuropathic disease as a consequence of mutations in a sodium pump gene]
, 2006 Jan 28 , 150 (194-6).

348

Fertleman CR et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes.
Neuron, 2006 Dec 7 , 52 (767-74).

349

Catterall WA et al. Painful channels.
Neuron, 2006 Dec 7 , 52 (743-4).

350

Cox JJ et al. An SCN9A channelopathy causes congenital inability to experience pain.
Nature, 2006 Dec 14 , 444 (894-8).

351

Gardiner M Molecular genetics of infantile nervous system channelopathies.
Early Hum. Dev., 2006 Dec , 82 (775-9).

352

Diss JK et al. Brn-3a neuronal transcription factor functional expression in human prostate cancer.
Prostate Cancer Prostatic Dis., 2006 , 9 (83-91).

353

Saleh S et al. Electrophysiological and molecular identification of voltage-gated sodium channels in murine vascular myocytes.
J. Physiol. (Lond.), 2005 Oct 1 , 568 (155-69).

354

Michiels JJ et al. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7.
Arch. Neurol., 2005 Oct , 62 (1587-90).

355

Jo T et al. Acute and chronic effects of eicosapentaenoic acid on voltage-gated sodium channel expressed in cultured human bronchial smooth muscle cells.
Biochem. Biophys. Res. Commun., 2005 Jun 17 , 331 (1452-9).

356

Drenth JP et al. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.
J. Invest. Dermatol., 2005 Jun , 124 (1333-8).

357

Burns TM et al. Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia.
Br. J. Dermatol., 2005 Jul , 153 (174-7).

358

Rush AM et al. Contactin regulates the current density and axonal expression of tetrodotoxin-resistant but not tetrodotoxin-sensitive sodium channels in DRG neurons.
Eur. J. Neurosci., 2005 Jul , 22 (39-49).

359

Marionneau C et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart.
J. Physiol. (Lond.), 2005 Jan 1 , 562 (223-34).

360

Yeomans DC et al. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents.
Hum. Gene Ther., 2005 Feb , 16 (271-7).

361

Meisler MH et al. Sodium channel mutations in epilepsy and other neurological disorders.
J. Clin. Invest., 2005 Aug , 115 (2010-7).

362

Dib-Hajj SD et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons.
Brain, 2005 Aug , 128 (1847-54).

363

Diss JK et al. A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo.
Prostate Cancer Prostatic Dis., 2005 , 8 (266-73).

364

Mechaly I et al. Molecular diversity of voltage-gated sodium channel alpha subunits expressed in neuronal and non-neuronal excitable cells.
Neuroscience, 2005 , 130 (389-96).

365

Nassar MA et al. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8.
, 2005 , 1 (24).

366

Cummins TR et al. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.
J. Neurosci., 2004 Sep 22 , 24 (8232-6).

367

Raymond CK et al. Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia.
J. Biol. Chem., 2004 Oct 29 , 279 (46234-41).

368

Wood JN et al. Voltage-gated sodium channels and pain pathways.
J. Neurobiol., 2004 Oct , 61 (55-71).

369

Wada A et al. Regulation of cell surface expression of voltage-dependent Nav1.7 sodium channels: mRNA stability and posttranscriptional control in adrenal chromaffin cells.
Front. Biosci., 2004 May 1 , 9 (1954-66).

370

Leipold E et al. Combinatorial interaction of scorpion toxins Lqh-2, Lqh-3, and LqhalphaIT with sodium channel receptor sites-3.
Mol. Pharmacol., 2004 Mar , 65 (685-91).

371

Yang Y et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.
J. Med. Genet., 2004 Mar , 41 (171-4).

372

Jo T et al. Voltage-gated sodium channel expressed in cultured human smooth muscle cells: involvement of SCN9A.
FEBS Lett., 2004 Jun 4 , 567 (339-43).

373

Chevrier P et al. Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine.
Br. J. Pharmacol., 2004 Jun , 142 (576-84).

374

McNulty MM et al. State-dependent mibefradil block of Na+ channels.
Mol. Pharmacol., 2004 Dec , 66 (1652-61).

375

Nassar MA et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain.
Proc. Natl. Acad. Sci. U.S.A., 2004 Aug 24 , 101 (12706-11).

376

Vijayaragavan K et al. Modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by protein kinase A and protein kinase C.
J. Neurophysiol., 2004 Apr , 91 (1556-69).

377

Herzog RI et al. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons.
J. Physiol. (Lond.), 2003 Sep 15 , 551 (741-50).

378

Chen H et al. Differential sensitivity of sodium channels from the central and peripheral nervous system to the scorpion toxins Lqh-2 and Lqh-3.
Eur. J. Neurosci., 2002 Aug , 16 (767-70).

379

Vijayaragavan K et al. Gating properties of Na(v)1.7 and Na(v)1.8 peripheral nerve sodium channels.
J. Neurosci., 2001 Oct 15 , 21 (7909-18).

380

Diss JK et al. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines.
Prostate, 2001 Aug 1 , 48 (165-78).

381

Kozak CA et al. Genetic mapping of the peripheral sodium channel genes, Scn9a and Scn10a, in the mouse.
Mamm. Genome, 1996 Oct , 7 (787-8).

382

Beckers MC et al. A new sodium channel alpha-subunit gene (Scn9a) from Schwann cells maps to the Scn1a, Scn2a, Scn3a cluster of mouse chromosome 2.
Genomics, 1996 Aug 15 , 36 (202-5).